Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Verona, NJ
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Verona, NJ
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Portland, OR
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Richmond, VA
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
mi
from
Calgary,
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
mi
from
Calgary,
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
mi
from
Washington Park, MD
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
mi
from
Washington Park, MD
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Saint Joseph, MO
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
New York, NY
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Cranston, RI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Cranston, RI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Houston, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
San Antonio, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Fort Smith, AR
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Fresno, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Fresno, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Irvine, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Irvine, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Los Angeles, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Oceanside, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Santa Ana, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Denver, CO
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
North Logan, CT
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
North Logan, CT
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Atlanta, GA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Chicago, IL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Dundee, IL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Dundee, IL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
New Albany, IN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
New Albany, IN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Overland Park, KA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
New Orleans, LA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Andover, MA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Andover, MA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Bay City, MI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Bay City, MI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Fridley, MN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
High Point, NC
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
High Point, NC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Cincinnati, OH
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Philadelphia, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Greer, SC
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Greer, SC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Dallas, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Webster, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Norfolk, VA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Seattle, WA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Surrey,
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
West Bloomfield Township, MI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
West Bloomfield Township, MI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated:  10/18/2017
GSK Investigational Site
mi
from
Saint Joseph, MO
A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)
Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis
Status: Enrolling
Updated: 10/18/2017
GSK Investigational Site
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Status: Enrolling
Updated:  10/24/2017
University of Michigan
mi
from
Ann Arbor, MI
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma
Status: Enrolling
Updated: 10/24/2017
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Status: Enrolling
Updated:  10/25/2017
Seton Family of Hospitals- Trinity Clinic
mi
from
Austin, TX
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Status: Enrolling
Updated: 10/25/2017
Seton Family of Hospitals- Trinity Clinic
mi
from
Austin, TX
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated:  10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)
A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).
Status: Enrolling
Updated: 10/30/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials